The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

Eight NHS cancer centers will examine tumors from patients with exceptional survival times, focusing on three aggressive cancer types.

Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...

The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended approval for Bristol Myers Squibb's Augtyro (repotrectinib) as a treatment for ...

NEW YORK – The US Food and Drug Administration has granted the Global Institute of Stem Cell Therapy and Research (Giostar) permission to begin a Phase II trial of DT2-SCT, an autologous stem cell ...